Facts and uncertainties in monitoring treatment response in chronic myeloid leukaemia

Leukemia Research

Volumn 33, Issue 9, 2009, Pages 1151-1155

  Clark, Richard E ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Chronic myeloid leukaemia; Drug monitoring; Imatinib; Mutation; Tyrosine kinase inhibitor

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

BONE MARROW; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; EDITORIAL; GENE MUTATION; HEMATOLOGY; HUMAN; LEUKEMIA RELAPSE; MOLECULAR GENETICS; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MONITORING, PHYSIOLOGIC; MUTATION; PIPERAZINES; PYRIMIDINES;

EID: 67549124656     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.04.001     Document Type: Editorial

References (62)

1. Hehlmann R., Hochhaus A., and Baccarani M. Chronic myeloid leukaemia. Lancet 370 (2007) 342-350
2. Baccarani M., Saglio G., Goldman J., et al. Evolving concepts in the management of chronic myeloid leukaemia. Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108 (2006) 1809-1820
3. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia, V.2.2009. Available at http://www.nccn.org/professionals/physician_gls/PDF/cml.pdf (accessed April 2009).
4. Hazarika M., Jiang X., Liu Q., et al. Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 14 (2008) 5325-5331
5. Brave M., Goodman V., Kaminskas E., et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 14 (2008) 352-359
6. Weisberg E., Manley P.W., Breitenstein W., et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7 (2005) 129-141
7. Lombardo L.J., Lee F.Y., Chen P., et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47 (2004) 6658-6661
8. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 (2003) 994-1004
9. Druker B.J., Guilhot F., O'Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355 (2006) 2408-2417
10. Hochhaus A., Druker B.J., Larson R.A.., et al. IRIS 6-year follow-up: sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood (ASH Annual Meeting Abstracts) 110 (2007) 15a-16a [abstract 25]
11. Kantarjian H., O'Brien S., Shan J., et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?. Cancer 112 (2008) 837-845
12. Lucas C.M., Wang L., Austin G.M., et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia 22 (2008) 1963-1966
13. de Lavallade H., Apperley J.F., Khorashad J.S., et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 26 (2008) 3358-3363
14. Sawyers C.L., Hochhaus A., Feldman E., et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99 (2002) 3530-3539
15. Talpaz M., Silver R.T., Druker B.J., et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99 (2002) 1928-1937
16. Guilhot F., Larson R.A., O'Brien S.G., et al. Time to complete cytogenetic response does not affect long-term outcomes for patients on imatinib therapy. Blood (ASH Annual Meeting Abstracts) 110 (2007) 16a [abstract 27]
17. Iacobucci I., Rosti G., Amabile M., et al. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. J Clin Oncol 24 (2006) 454-459
18. Wang L., Pearson K., Ferguson J.E., et al. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol 120 (2003) 990-999
19. Kantarjian H.M., Talpaz M., O'Brien S., et al. Survival benefit with imatinib mesylate versus interferon alpha-based regimens in newly diagnosed chronic phase chronic myelogenous leukemia. Blood 108 (2006) 1835-1840
20. Palandri F., Iacobucci I., Martinelli G., et al. Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, Philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. J Clin Oncol 26 (2008) 106-111
21. Marin D., Kaeda J., Szydlo R., et al. Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia 19 (2005) 507-512
22. Hughes T., Deininger M., Hochhaus A., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108 (2006) 28-37
23. Press R.D., Love Z., Tronnes A.A., et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood 107 (2006) 4250-4256
24. Marin D., Milojkovic D., Olavarria E., et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 112 (2008) 4437-4444
25. Iacobucci I., Saglio G., Rosti G., et al. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res 12 (2006) 3037-3042
26. Paschka P., Müller M.C., Merx K., et al. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia 17 (2003) 1687-1694
27. Cortes J., Talpaz M., O'Brien S., et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 11 (2005) 3425-3432
28. Branford S., Rudzki Z., Parkinson I., et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 104 (2004) 2926-2932
29. Wang L., Knight K., Lucas C., et al. The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. Haematologica 91 (2006) 235-239
30. Press R.D., Galderisi C., Yang R., et al. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res 13 (2007) 6136-6143
31. Kantarjian H., Schiffer C., Jones D., et al. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 111 (2008) 1774-1780
32. O'Dwyer M.E., Mauro M.J., Blasdel C., et al. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood 103 (2004) 451-455
33. Soverini S., Colarossi S., Gnani A., et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 12 (2006) 7374-7379
34. Apperley J.F. Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8 (2007) 1018-1029
35. Jabbour E., Kantarjian H., Jones D., et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20 (2006) 1767-1773
36. Jabbour E., Kantarjian H., Jones D., et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 112 (2008) 53-55
37. Nicolini F.E., Corm S., Le Q.H., et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(varphi)-LMC GROUP). Leukemia 20 (2006) 1061-1066
38. Branford S., Rudzki Z., Walsh S., et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102 (2003) 276-283
39. Soverini S., Martinelli G., Rosti G., et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 23 (2005) 4100-4109
40. Khorashad J.S., de L.H., Apperley J.F., et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 26 (2008) 4806-4813
41. Nicolini F.E., Corm S., Le Q.H., et al. The prognosis impact of BCR-ABL P-loop mutations: worse or not worse?. Leukemia 21 (2007) 193-194
42. Kantarjian H., Pasquini R., Hamerschlak N., et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 109 (2007) 5143-5150
43. Cortes J., Jabbour E., Kantarjian H., et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 110 (2007) 4005-4011
44. Shah N.P., Skaggs B.J., Branford S., et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 117 (2007) 2562-2569
45. Soverini S., Colarossi S., Gnani A., et al. Resistance to to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 92 (2007) 401-404
46. Khorashad J.S., Milojkovic D., Mehta P., et al. In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood 111 (2008) 2378-2381
47. Hochhaus A., Kim D.W., Martinelli G., et al. Nilotinib efficacy according to baseline BCR-ABL mutations in patients with imatinib-resistant chronic myeloid leukemia in chronic phase (CML-CP). Blood (ASH Annual Meeting Abstracts) (2008) [abstract 3216]
48. Soverini S., Martinelli G., Amabile M., et al. Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to imatinib. Clin Chem 50 (2004) 1205-1213
49. Ernst T., Erben P., Muller M.C., et al. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica 93 (2008) 186-192
50. Chu S., Xu H., Shah N.P., et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 105 (2005) 2093-2098
51. Sherbenou D.W., Wong M.J., Humayun A., et al. Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia 21 (2007) 489-493
52. Picard S., Titier K., Etienne G., et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109 (2007) 3496-3499
53. Larson R.A., Druker B.J., Guilhot F., et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111 (2008) 4022-4028
54. Forrest D.L., Trainor S., Brinkman R.R., et al. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leuk Res 33 (2009) 271-275
55. White D., Saunders V., Grigg A., et al. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J Clin Oncol 25 (2007) 4445-4451
56. Crossman L.C., Druker B.J., Deininger M.W., et al. hOCT 1 and resistance to imatinib. Blood 106 (2005) 1133-1134
57. White D.L., Saunders V.A., Dang P., et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110 (2007) 4064-4072
58. Wang L., Giannoudis A., Lane S., et al. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 83 (2008) 258-264
59. White D.L., Saunders V.A., Dang P., et al. OCT-1 mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107); reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108 (2006) 697-704
60. Giannoudis A., Davies A., Lucas C.M., et al. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 112 (2008) 3348-3354
61. Illmer T., Schaich M., Platzbecker U., et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 18 (2004) 401-408
62. Brendel C., Scharenberg C., Dohse M., et al. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 21 (2007) 1267-1275